Six years later, in 2015, Kite bought T Cell Factory in Amsterdam, a spin-off from NKI. In 2009, Kite was established in Santa Monica, California, USA. Additionally, it really is a precision task to transport living cells this has to be done under very strict conditions in terms of time and temperature control.’ ‘That was not ideal, considering all their options have been exhausted and the people in need of this treatment are critically ill, and often have little time left. ‘Before our production facility was located here in the Amsterdam area, the only way Kite could supply patients in Europe with cell therapy, was to fly their cells to and from our production site in Los Angeles’, says Louis van de Wiel, who is VP Operations and Site Head for Kite EU B.V. These ‘reprogrammed’ cells are designed to recognize and combat the cancer. Here, these T-cells are engineered and multiplied, after which they are sent back and administered to the same patient. This is taken from a patient, in a European hospital, and is then transported to the Kite facility in the Netherlands. More specifically, cell therapy is tailor-made for each patient and gives the immune system extra ammunition to attack cancer itself.Īpproved by the European Medicines Agency (EMA) in 2018, Kite’s cell therapy, in essence, works with a type of white blood cell (T-cell). Cell therapy is a relatively new and highly individualized treatment providing care for patients with a specific type of blood cancer, for whom other approaches have failed. With its cell therapy, the company is striving to make a difference for patients in Europe. One of the main factors influencing Kite’s decision to open a brand-new manufacturing facility, here in 2020, was the vitality of the Dutch life sciences & health sector. With its innovative cell therapy, Kite is at the forefront of a new way of treating cancer. This was a very heavily pretreated group of patients with a very poor prognosis, and yet you had overall response rates above 80%, and you had complete response rates above 50%, which just absolutely trounces the historical norms for this patient population.Biotech company Kite, a part of Gilead Sciences Inc., is providing cancer treatment from its production facility near Amsterdam, the Netherlands, enabling it to serve patients in Europe. And it's just pretty remarkable, especially when you're talking about non-Hodgkin lymphoma in the patient study group that was evaluated that's backing up Axi-Cel. You've now unleashed the power of the human body again to find and cure a disease. So, you've basically given them the mailing address - go seek out and find and destroy these cancer cells.Īnd I think that's why people are so excited about the potential behind this. Well, what research has discovered is, if they take T-cells out of a patient's body, send them off to a separate facility where scientists can work some magic on them and reengineer them in a certain way, then send those cells back to the patient, put them inside the body, you've removed the invisibility cloak, and you've done that by telling the T-cells specifically to go after a protein called CD19 that is expressed primarily on the surface of these cancer cells.
Kite pharma how to#
But cancer is a tricky, tricky disease, and it knows how to evade detection. The immune system, its job is to go out, seek out infections, seek out cancer cells, and kill them. Now, of course, will the FDA jump the gun on that one, too? Who knows?Ĭampbell: Yeah, I'd be right there. Axi-Cel has already completed phase 3 testing and has a PDUFA date with the FDA on November 29. The long name, trust me, you don't want to hear me try to pronounce it, because I'll just butcher it. As well, though, you have this lead drug, it's called Axi-Cel. That represents an enormous optionality and number of opportunities for them. So, that's a very expansive pipeline that should help Gilead, hopefully, get some wins over the next many several different years. Michael Douglass: It's interesting, because if you look at Kite's pipeline, they have about a dozen drugs in phase 1 or earlier. Todd Cambell: One of the most anticipated news events of the year was, what will Gilead Sciences do with its absolutely mountainous and growing pile of cash? And we found out, obviously, this week that it wants to become a major player in oncology, and it's willing to do that not by buying an individual drug, but buying a platform that will allow it to develop drug after drug after drug for increasingly more indications, and that platform is CAR-T.
0 kommentar(er)
